Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.…
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
Cellectis (NASDAQ: CLLS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 224 employees.
The shares were at 0.9209 USD on 20 November 2026, down 74.8% over 52 weeks. Its 52-week range is 0.8808 USD to 5.450 USD: the price is 83.1% below the high and 4.6% above the low.
Its market capitalisation is 92.76M USD.
Cellectis reports return on equity of -89.1%, an operating margin of -384.9% and revenue down 85.4% year over year.
It holds more cash than debt, a net cash position of 120.82M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.